Publications by authors named "Gabriell Borgato"
Article Synopsis
- * Studies indicate that cancer stem cells (CSCs) in OSCC exhibit resistance to CDDP, leading researchers to explore new therapeutic approaches targeting these cells.
- * The research assessed the effects of the NFκB inhibitor emetine and the HDAC inhibitor SAHA on OSCC CSCs, showing that both inhibitors can disrupt these resistant cells by enhancing histone acetylation and inhibiting the NFκB pathway, with combined treatment yielding similar results to emetine alone.
Article Synopsis
- Drug resistance in mucoepidermoid carcinomas (MEC) leads to issues like tumor recurrence and metastasis, primarily driven by cancer stem cells (CSCs).
- Previous research indicated that tumors use NFkB signaling for chemotherapy resistance, and targeting the epigenome can help manage CSC populations.
- The study found that using low doses of NFkB inhibitor emetine and HDAC inhibitor SAHA is effective against MEC CSCs; also, combining emetine with Cisplatin (CDDP) is a promising strategy for treating the non-CSC tumor cells in MEC.
Combined therapy with cisplatin and 5-AZA-2CdR modifies methylation and expression of DNA repair genes in oral squamous cell carcinoma.
Int J Clin Exp Pathol
March 2022
The methylation and expression of DNA repair system genes has been studied in several tumor types. These genes have been associated with resistance to chemotherapy treatments by epigenetic regulation. Studies have yet to show the effects of combined therapy using an epigenetic drug (5-aza-2CdR) and cisplatin (CDDP) on DNA repair genes in oral squamous cell carcinoma (OSCC).
View Article and Find Full Text PDFAim: To evaluate the potential use of Cephaeline as a therapeutic strategy to manage mucoepidermoid carcinomas (MEC) of the salivary glands.
Material And Methods: UM-HMC-1, UM-HMC-2, and UM-HMC-3A MEC cell lines were used to establish the effects of Cephaeline over tumor viability determined by MTT assay. In vitro wound healing scratch assays were performed to address cellular migration while immunofluorescence staining for histone H3 lysine 9 (H3k9ac) was used to identify the acetylation status of tumor cells upon Cephaeline administration.
Head and neck cancer patient-derived xenograft models - A systematic review.
Crit Rev Oncol Hematol
November 2020
Background: Patient-derived xenograft (PDX) involve the direct surgical transfer of fresh human tumor samples to immunodeficient mice. This systematic review aimed to identify publications of head and neck cancer PDX (HNC-PDX) models, describing the main methodological characteristics and outcomes.
Methods: An electronic search was undertaken in four databases, including publications having used HNC-PDX.
Loss of PTEN sensitizes head and neck squamous cell carcinoma to 5-AZA-2'-deoxycytidine.
Oral Surg Oral Med Oral Pathol Oral Radiol
August 2020
Objective: Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer associated with poor survival. Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene involved in the maintenance of stem cells. DNA methylation is a known epigenetic modification involved in tumor progression.
View Article and Find Full Text PDFHead and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide and is characterized by a fast-paced growth. Like other solid tumors, the HNSCC growth rate results in the development of hypoxic regions identified by the expression of hypoxia-inducible factor 1α (HIF-1α). Interestingly, clinical data have shown that pharmacological induction of intratumoral hypoxia caused an unexpected rise in tumor metastasis and the accumulation of cancer stem cells (CSCs).
View Article and Find Full Text PDF5-Aza-CdR promotes partial MGMT demethylation and modifies expression of different genes in oral squamous cell carcinoma.
Oral Surg Oral Med Oral Pathol Oral Radiol
May 2019
Objective: Treatment strategies for oral squamous cell carcinoma (OSCC) vary, depending on the stage of diagnosis. Surgery and radiotherapy are options for localized lesions for stage I patients, whereas chemotherapy is the main treatment for metastatic OSCC. However, aggressive tumors can relapse, frequently causing death.
View Article and Find Full Text PDF